The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 29 rounds in the feed, most often in Biotech.
We invest in the innovators behind the miracles of science who are passionate about improving human health.
Corporate venture armsanofiventures.comRounds from 2021-01-07 to 2026-11-18
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
VitriVax A vaccine development and formulation technology company | Series C Verified against 4 of 45 sources | $87M | 2026-11-18 | [ LEAD ] |
T-Therapeutics A biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases | Series B |
| $133M |
| 2026-11-05 |
| [ PART ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series D Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $66M | 2026-08-18 | [ PART ] |
AdvanCell AdvanCell is developing targeted alpha radiotherapies for cancer. | Series D Verified against 4 of 6 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $315M | 2026-07-15 | [ PART ] |
Bionyra Pharma Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation biologics for severe immune-mediated inflammatory diseases. | Series A Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2026-06-22 | [ PART ] |
Windward Bio Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD. | Crossover financing Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2026-05-04 | [ PART ] |
Alveus Therapeutics Alveustx specializes in developing next-generation treatments for obesity and metabolic diseases. | Series A ext. Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $197M financing total | 2026-02-24 | [ PART ] |
Korsana Korsana develops advanced therapeutics aimed at treating neurodegenerative diseases, particularly focusing on Alzheimer's disease. | Series A Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2026-02-18 | [ PART ] |
Diagonal Therapeutics They develop innovative clustering antibodies for the treatment of genetic diseases. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2026-01-08 | [ LEAD ] |
Alveus Therapeutics Alveustx specializes in developing next-generation treatments for obesity and metabolic diseases. | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $160M | 2026-01-08 | [ PART ] |
ELECTRA Therapeutics Electra Therapeutics develops SIRP-directed therapies designed to improve outcomes for patients with immune-mediated diseases and cancer. | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $183M | 2025-10-22 | [ PART ] |
Expedition Therapeutics Expedition Therapeutics develops novel treatments for inflammatory and respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD). | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2025-10-09 | [ PART ] |
STAR Therapeutics They develop and provide antibody therapies for patients with serious diseases. | Series D Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2025-09-30 | [ LEAD ] |
Draig A biotech company | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $140M (£107 million) financing total | 2025-06-18 | [ PART ] |
SpliceBio SpliceBio develops next-generation gene therapies using their proprietary Protein Splicing platform, targeting diseases caused by mutations in large genes. | Series B Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $135M | 2025-06-11 | [ LEAD ] |
Granite Bio Granitebio is a biotechnology company developing innovative therapies focusing on inflammatory, autoimmune, and fibrotic diseases with first-in-class antibodies. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $70M | 2025-04-24 | [ LEAD ] |
Glycomine Glycomine develops replacement therapies for rare genetic diseases, particularly focusing on PMM2-CDG treatments. | Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-04-16 | [ PART ] |
Latigo Biotherapeutics Latigo is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2025-03-17 | [ PART ] |
Curevo Curevo Inc. develops an adjuvanted subunit vaccine for the prevention of shingles in adults. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $110M | 2025-03-17 | [ PART ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series C Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-02-12 | [ PART ] |
AdvanCell AdvanCell is developing targeted alpha radiotherapies for cancer. | Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $112M | 2025-02-03 | [ LEAD ] |
Mirador Therapeutics Mirador Therapeutics focuses on developing precision medicines for immune-mediated inflammatory and fibrotic diseases. | Series A Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $400M | 2024-03-21 | [ PART ] |
T-Therapeutics A biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) therapeutics for cancer and autoimmune diseases | Series A Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $59.8M | 2023-11-15 | [ PART ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $155M | 2023-08-17 | [ PART ] |
OMass Therapeutics A UK based biotechnology company developing small molecule therapeutics against highly validated targets | Series B ext. Developing, 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $12.5M | 2023-05-15 | [ PART ] |
Novartis-partnered biotech A biotechnology company pioneering the discovery of precision covalent medicines | Series A Verified against 2 of 4 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $70M | 2022-10-14 | [ LEAD ] |
OMass Therapeutics A UK based biotechnology company developing small molecule therapeutics against highly validated targets | Series B Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2022-04-28 | [ LEAD ] |
Glycomine Glycomine develops replacement therapies for rare genetic diseases, particularly focusing on PMM2-CDG treatments. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $35M | 2021-06-23 | [ LEAD ] |
Abcuro Breakthrough therapies for autoimmune diseases and cancer for patients with specific conditions. | Series A Developing, 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $42M | 2021-01-07 | [ LEAD ] |